AIDP, Inc., the distributors of MagteinTM magnesium L-threonate, has been awarded two patents for magnesium compositions and uses for cognitive function and neurological disorders. Magnesium L-threoate is expected to be the next breakthrough ingredient and these patents protect Magtein’s unique magnesium compositions and its use for any magnesium L-threonate-containing food, nutritional supplements, and drugs for enhancing cognitive function or ameliorating the effects of a neurological disorder.
The use of these products is applicable for improving the health of people suffering from loss of cognitive function, loss of memory, Alzheimer’s disease, depression, attention deficit hyperactivity disorder, Amyotrophic lateral sclerosis (ALS), Parkinson’s disease, migraine, anxiety disorder, and mood disorder, as some examples of cognitive and neurological disorders. “We truly believe that Magtein is a game changing ingredient that will benefit millions of busy and stressed consumers by helping to improve their quality of life,” says Edward Lee Ph.D., AIDP president.
